You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
OsteoCool™ Radiofrequency Ablation is a minimally invasive, palliative option for patients with bone tumors in the spine and in peripheral bone. Ablation times vary between 6.5 to 15 minutes per affected area.
Physicians can treat patients with OsteoCool right away, while other treatments, like radiation therapy, are being planned. Additionally, OsteoCool does not disrupt systemic therapies and it can be used before, during or after radiation therapy. If conventional cancer therapies are considered ineffective or too slow-acting, or if they cause unacceptable side effects,1 consider addressing your patient's cancer pain with the OsteoCool procedure.
Radiation therapy (RT) is the gold standard palliative treatment for patients with bone metastases. But there may be patients who cannot or do not benefit from RT as the only treatment for pain palliation.
Metastatic bone disease pain is multifaceted. While some pain derives from biological sources such as cytokine release, other pain sources are mechanical.2 We’re actively collaborating across specialties to find treatment algorithms that address the needs of patients with bone metastases.
“It’s so important to identify new treatment opportunities and provide innovative therapies like OsteoCool to help us achieve positive outcomes with this patient population. At Duke, we have brought together a multidisciplinary team around spinal metastases management and have created a tumor board system which includes Interventionalists, Medical Oncology, Radiation Oncology, and Palliative Care. Each person comes to the table with their own thorough knowledge of how to treat this disease process. And, when you bring all of us together, we’ve found that we can do much more for these patients than we can independently." – Tom Hopkins, MD, Duke University School of Medicine, Durham, NC.
Discover how Interventionalists and Oncologists work together to help patients suffering from Metastatic Bone Disease. The Medtronic Interventional Oncology VuMedi channel lets you learn at your leisure. Pre-recorded programs are now available for viewing. VuMedi is a public site that offers training and education to physicians on specific topics and is free to join and access.
Cory’s breast cancer metastasized to her spine and sacrum causing unrelenting lower back pain that brought her into the ER. Not wanting to remain on opioids for her pain, Cory asked her doctor about other options. Dr. Ramsin Benyamin at Millennium Pain Center in Normal, IL offered to treat Cory’s cancer pain with OsteoCool.
HEAR CORY’S STORY
Learn how the OsteoCool procedure affected Cory’s quality of life.
INDICATIONS
RISKS
Gangi et al. Image-Guided Ablation Therapy of Bone Tumors. Elsevier Inc, 2009.
Wallace AN, Greenwood TJ, Jennings JW. Radiofrequency ablation and vertebral augmentation for palliation of painful spinal metastases. J Neurooncol. 2015; 124(1); 15; 707-712.
See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu
The views and opinions of the HCP expressed therein should be interpreted as personal views. They are completely independent and do not necessarily reflect the opinions of Medtronic.